Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.90 USD
Change Today -0.60 / -13.33%
Volume 39.0K
MYOS On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

myos corp (MYOS) Key Developments

MYOS Corporation, Q1 2015 Earnings Call, May 14, 2015

MYOS Corporation, Q1 2015 Earnings Call, May 14, 2015

MYOS Corporation, Q4 2014 Earnings Call, Mar 30, 2015

MYOS Corporation, Q4 2014 Earnings Call, Mar 30, 2015

MYOS Corporation's Preclinical Study of Fortetropin's Mechanism of Action Demonstrate Regulatory Effects on Three Key Muscle Health Pathways

MYOS Corporation announced that its mechanism of action studies have identified three key molecular signaling pathways in which Fortetropin™ exhibits regulatory effects. In addition to reducing serum myostatin levels, MYOS recently completed a preclinical mechanism of action study that demonstrated Fortetropin's activity in mTOR and Ubiquitin, two other crucial signaling pathways in the growth and maintenance of healthy muscle. Myostatin is a naturally occurring regulatory protein which prevents muscle growth. Myostatin serum levels increase as people age which can lead to age-related muscle loss or sarcopenia. Fortetropin's ability to reduce serum myostatin levels has been clinically proven. Regulation of myostatin may be a key element in the treatment of sarcopenia. In addition to myostatin regulation, MYOS' preclinical data also showed that Fortetropin up-regulates the mTOR regulatory pathway. The mTOR pathway is responsible for production of a protein kinase related to cell growth and proliferation that increases skeletal muscle mass. Up-regulation of the mTOR pathway is important in preventing muscle atrophy. Fortetropin's ability to affect the mTOR pathway may have a significant impact in treating patients suffering from degenerative muscle diseases and suggests that Fortetropin-based products may help slow muscle loss secondary to immobility and denervation. Finally, the Company's recent animal model study demonstrated that Fortetropin acts to reduce the synthesis of proteins in the Ubiquitin pathway, a highly selective, tightly regulated system that serves to activate muscle breakdown. Over-production in the Ubiquitin pathway is responsible for muscle degradation. Fortetropin's ability to regulate production in the Ubiquitin pathway may have significant implications for repairing age-related muscle loss and for patients suffering from chronic diseases causing cachexia.

MYOS Corporation Appoints EisnerAmper LLP as Independent Registered Public Accounting Firm

MYOS Corporation Company held its annual meeting of stockholders on December 22, 2014 ratified the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2014.

MYOS Corporation Approves Amendment to Articles of Incorporation

MYOS Corporation held its annual meeting of stockholders on December 22, 2014, approved a Certificate of amendment to its articles of incorporation, as amended (the 'Articles of Incorporation') with the Secretary of State of the State of Nevada to effect an increase in the aggregate number of authorized shares of common stock by 2,000,000 shares to 8,000,000 shares.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYOS:US $3.90 USD -0.60

MYOS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MYOS.
View Industry Companies
 

Industry Analysis

MYOS

Industry Average

Valuation MYOS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.7x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYOS CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.